Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Goodwill & Intangibles (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Goodwill & Intangibles for 8 consecutive years, with $701000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Goodwill & Intangibles rose 156.78% to $701000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $701000.0, a 156.78% increase, with the full-year FY2024 number at $701000.0, up 156.78% from a year prior.
  • Goodwill & Intangibles was $701000.0 for Q4 2024 at Gyre Therapeutics, up from $273000.0 in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $701000.0 in Q4 2024 to a low of $273000.0 in Q4 2023.
  • A 3-year average of $423666.7 and a median of $297000.0 in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: dropped 8.08% in 2023, then soared 156.78% in 2024.
  • Gyre Therapeutics' Goodwill & Intangibles stood at $297000.0 in 2022, then fell by 8.08% to $273000.0 in 2023, then skyrocketed by 156.78% to $701000.0 in 2024.
  • Per Business Quant, the three most recent readings for GYRE's Goodwill & Intangibles are $701000.0 (Q4 2024), $273000.0 (Q4 2023), and $297000.0 (Q4 2022).